We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-15.5%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$351M
Cap. Flow
+$73.5M
Cap. Flow %
5.83%
Top 10 Hldgs %
73.34%
Holding
36
New
3
Increased
5
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$94.4M
2
XLO icon
Xilio Therapeutics
XLO
+$47.8M
3
MRSN
Mersana Therapeutics
MRSN
+$13.2M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.63M
5
TSVT
2seventy bio
TSVT
+$5.6M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$62.1M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$18.9M
3
IVVD icon
Invivyd
IVVD
+$14.3M
4
BLUE
bluebird bio
BLUE
+$3.45M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$2.49M

Sector Composition

Rank Sector Weight
1 Healthcare 95.4%
2 Financials 3.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$299M 23.75%
4,831,307
– –
DVAX
2
DELISTED
Dynavax Technologies
DVAX
$118M 9.39%
8,415,000
– –
RPID icon
3
Rapid Micro Biosystems
RPID
$86.2M
$89.7M 7.12%
8,434,560
– –
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.18B
$82.5M 6.55%
3,979,292
– –
EQRX
5
DELISTED
EQRx, Inc. Common Stock
EQRX
$68.2M 5.41%
+10,003,573
New +$94.4M
NUVL
6
DELISTED
Nuvalent
NUVL
$65.3M 5.18%
3,428,014
– –
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.92B
$57.7M 4.57%
2,029,701
+350,000
+21% +$8.63M
CCCC icon
8
C4 Therapeutics
CCCC
$412M
$52.9M 4.19%
1,642,210
+1
+0% +$40
PHVS icon
9
Pharvaris
PHVS
$2.44B
$45.8M 3.63%
3,180,601
– –
XLO icon
10
Xilio Therapeutics
XLO
$60.3M
$44.9M 3.56%
+200,387
New +$47.8M
ANNX icon
11
Annexon
ANNX
$886M
$37.2M 2.95%
3,241,628
– –
NRIX icon
12
Nurix Therapeutics
NRIX
$2.65B
$37.2M 2.95%
1,284,313
-1
-0% -$30
MRSN
13
DELISTED
Mersana Therapeutics
MRSN
$33.5M 2.66%
215,427
+67,600
+46% +$13.2M
APTX
14
DELISTED
Aptinyx Inc. Common Stock
APTX
$23.7M 1.88%
8,891,758
– –
AVIR icon
15
Atea Pharmaceuticals
AVIR
$420M
$22.2M 1.76%
2,485,638
-1,214,362
-33% -$18.9M
TNGX icon
16
Tango Therapeutics
TNGX
$4.41B
$21M 1.67%
1,921,790
– –
SYRS
17
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$20.4M 1.62%
626,442
+47,938
+8% +$1.94M
MRNS
18
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$17M 1.35%
1,431,058
– –
SVRA icon
19
Savara
SVRA
$1.19B
$14.4M 1.14%
11,622,598
– –
IVVD icon
20
Invivyd
IVVD
$218M
$14.1M 1.12%
1,937,207
-550,000
-22% -$14.3M
SLDB icon
21
Solid Biosciences
SLDB
$900M
$13.9M 1.1%
528,661
– –
SYRE icon
22
Spyre Therapeutics
SYRE
$9.25B
$13.5M 1.07%
113,908
– –
NAUT icon
23
Nautilus Biotechnolgy
NAUT
$115M
$10.4M 0.82%
2,000,000
– –
RACB
24
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$9.77M 0.77%
1,000,000
– –
ARYD
25
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$6.94M 0.55%
700,000
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q4 2021 Portfolio in Review

As of Q4 2021, Bain Capital Life Sciences Investors held 36 positions worth $1.26B, down 22% from $1.61B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Bain Capital Life Sciences Investors deployed $73.5M of net new capital in Q4 2021, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was EQRx, Inc. Common Stock: 10,003,573 shares worth $68.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Atea Pharmaceuticals, an estimated $18.9M trimmed.

  • Bain Capital Life Sciences Investors's largest Q4 2021 buy was EQRx, Inc. Common Stock: 10,003,573 shares worth $68.2M.
  • Bain Capital Life Sciences Investors added most to Mersana Therapeutics in Q4 2021, an estimated $13.2M increase.
  • Bain Capital Life Sciences Investors's biggest Q4 2021 reduction was Atea Pharmaceuticals, cutting an estimated $18.9M.
  • Bain Capital Life Sciences Investors fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $62.1M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 73% of its $1.26B portfolio in Q4 2021.
  • Bain Capital Life Sciences Investors opened 3 new positions and closed 2 in Q4 2021.
  • Bain Capital Life Sciences Investors's portfolio value fell 22% quarter-over-quarter to $1.26B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2021, filed 14 Feb 2022.